Intriguing article. It has been an interesting year. Hopefully this year will progress significantly farther than last year regarding the potential of ampakines but with a progressive growth of good clinical data.
It seems like last year was the start of some research being finalized with more potent cortex ampakines not just initiated via cortex,, if the Cx 717 and more recent compounds have demonstrated adequate safety along with adequate efficacy and evolving efficacy in multiple indications, then the next 3 years may be very interesting,,,, as long as Cortex is able to maintain its business viability without delisting.
With the seemingly excellent growing amount of research on indications which the cortex amapkines are focused on in addition to the growing amount of research on cortex ampakines, horrible economy or not, it seems increasingly unlikely for a deal not to happen where cortex can gain cashflow to operate adequately.
News 
Market Data 
Discover 
